What is BioAlert Solutions?
BioAlert Solutions is a specialized biotechnology enterprise headquartered in Sherbrooke, Quebec, focused on the development and commercialization of advanced optical detection systems. Since its inception in 2014, the company has distinguished itself through the successful validation of its flagship product, BioAlert Lp15, in real-world environments. The organization operates at the intersection of deep tech and industrial engineering, maintaining a multidisciplinary workforce that integrates expertise in biotechnology, optical sensing, and strategic market development. By providing robust, data-driven detection capabilities, the company serves as a critical partner for industrial entities seeking to optimize safety and efficiency through innovative technological integration.
How much funding has BioAlert Solutions raised?
BioAlert Solutions has raised a total of $2.5M across 1 funding round:
Angel/Seed
$2.5M
Angel/Seed (2025): $2.5M with participation from Cycle Capital Management, GreenSky Ventures, Fondaction, and Spring Impact Capital
Key Investors in BioAlert Solutions
Cycle Capital Management
Cycle Capital is a venture capital firm founded in 2009 that focuses on building innovative clean technology companies globally, managing a platform of seven investment funds across North America and Europe.
GreenSky Ventures
GreenSky Ventures is a Toronto-based firm that deploys capital into early-stage Canadian B2B start-ups, utilizing a strategy of extraordinary diligence across software, deep tech, and industrial technologies.
Fondaction
Founded in 1996, Fondaction invests in companies across Québec to help create and maintain quality jobs, contributing to a stronger, more equitable, and greener economy.
What's next for BioAlert Solutions?
Looking ahead, the strategic deployment of the $2.5M will likely focus on scaling production capabilities and expanding the commercial footprint of the BioAlert Lp15 platform. As the company moves into this enterprise-level growth phase, management is expected to prioritize the optimization of its supply chain and the acceleration of its go-to-market strategy. The backing from institutional investors suggests a long-term commitment to fostering sustainable innovation within the Canadian biotech ecosystem. Future milestones will likely involve the diversification of the product portfolio and the pursuit of international partnerships, leveraging the firm's established reputation for technical excellence to capture a larger share of the global detection technology market.
See full BioAlert Solutions company page
